Author: Editor

Adipocyte Vaccine: Presents Promising Results for Patients with Breast Cancer at SABCS 2022 Nora Disis MD By Nora Disis, MD Obesity is a major problem and a major cause of cancer, and there’s a particular type of obesity called inflammatory obesity where patients develop metabolic dysfunction. This dysfunction is really mediated or caused by immune cells and the type of immune cells it’s caused by are CD8 T-cells. The CD8 T-cells begin to recognize immunogenic proteins in fat, and they proliferate and compete for limited resources in the body fat. They become dysfunctional, and this is one of the ways…

Read More

Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD By Eunice Wang, MD So many patients who have acute myeloid leukemia receive treatment based on their prognostic classification, usually favorable, intermediate, or poor risk. So for patients with favorable risk and for patients with adverse risks the treatment regimens are clearly very straightforward. For patients (AML (Acute Myeloid Leukemia)) with intermediate risk, which represents about half of our nearly diagnosed patients who are fit and able to tolerate intensive chemotherapy, we give them a standard regimen 7+3. There is…

Read More

Lung Cancer Screening Program: Cedars-Sinai Implements a Streamlined Approach by Sara Ghandehari MD Sara Ghandehari, MD Cedars-Sinai is a non-profit hospital located in Los Angeles, California. They recently implemented a program aimed at increasing the frequency of lung cancer screening, which is currently very low. In this article, we will discuss Cedars-Sinai’s streamlined approach to lung cancer screening, the criteria used to identify eligible individuals, and how their program compares to other similar programs. According to Cedars-Sinai, the rate of lung cancer screening is very low. Nationally, only 6% of those who qualify for lung cancer screening are getting…

Read More

AI Risk Assessment: Sybil A Reliable Deep Learning Model for Predicting Future Lung Cancer Risk Dr. Florian Fintelmann By Florian Fintelmann, MD Sybil has not been used in other disease states. It was specifically developed to aid with the detection of lung cancer on low-dose chest CT, and those are chest CT exams that are performed specifically for lung cancer screenings, so all the data (sets) used to train, develop, tune, and test it were from low-dose chest CTs obtained specifically for lung cancer screening. Could you please explain to our viewers why Sybil has been chosen in this trial…

Read More

iFrame is not supported! The Importance of ctDNA in Breast Cancer Diagnosis and Treatment Planning Mridula George MD By Mridula George, MD Breast cancer (e.g., metastatic breast cancer) is the most common cancer in women worldwide, and early detection and personalized treatment are crucial for improving patient outcomes. Recently, the use of circulating tumor DNA (ctDNA) has emerged as a promising tool for the diagnosis and treatment of breast cancer. Initially, ctDNA (circulating tumor DNA) was mainly used in the metastatic setting, where it helped clinicians monitor disease progression and identify the most effective treatments. However, with the development of…

Read More

iFrame is not supported! Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD By Eunice Wang, MD So many patients who have acute myeloid leukemia receive treatment based on their prognostic classification, usually favorable, intermediate, or poor risk. So for patients with favorable risk and for patients with adverse risks the treatment regimens are clearly very straightforward. For patients (AML (Acute Myeloid Leukemia)) with intermediate risk, which represents about half of our nearly diagnosed patients who are fit and able to tolerate intensive chemotherapy, we give them a standard…

Read More

iFrame is not supported! Lung Cancer Screening Program: Cedars-Sinai Implements a Streamlined Approach by Sara Ghandehari MD Sara Ghandehari, MD Cedars-Sinai is a non-profit hospital located in Los Angeles, California. They recently implemented a program aimed at increasing the frequency of lung cancer screening, which is currently very low. In this article, we will discuss Cedars-Sinai’s streamlined approach to lung cancer screening, the criteria used to identify eligible individuals, and how their program compares to other similar programs. According to Cedars-Sinai, the rate of lung cancer screening is very low. Nationally, only 6% of those who qualify for lung…

Read More

Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD By Eunice Wang, MD So many patients who have acute myeloid leukemia receive treatment based on their prognostic classification, usually favorable, intermediate, or poor risk. So for patients with favorable risk and for patients with adverse risks the treatment regimens are clearly very straightforward. For patients (AML (Acute Myeloid Leukemia)) with intermediate risk, which represents about half of our nearly diagnosed patients who are fit and able to tolerate intensive chemotherapy, we give them a standard regimen 7+3. There is…

Read More

Lung Cancer Screening Program: Cedars-Sinai Implements a Streamlined Approach by Sara Ghandehari MD Sara Ghandehari, MD Cedars-Sinai is a non-profit hospital located in Los Angeles, California. They recently implemented a program aimed at increasing the frequency of lung cancer screening, which is currently very low. In this article, we will discuss Cedars-Sinai’s streamlined approach to lung cancer screening, the criteria used to identify eligible individuals, and how their program compares to other similar programs. According to Cedars-Sinai, the rate of lung cancer screening is very low. Nationally, only 6% of those who qualify for lung cancer screening are getting…

Read More

The Significance of ctDNA in Predicting Recurrence and Delaying Progression in Breast Cancer Patients Mridula George MD By Mridula George, MD Breast cancer is a complex disease that requires a timely and accurate diagnosis, appropriate treatment, and close monitoring of disease progression. Despite the advances in diagnostic and treatment modalities, disease recurrence and progression remain a significant concern for breast cancer patients. Therefore, identifying reliable biomarkers that can predict disease recurrence and monitor disease progression is crucial for improving patient outcomes. Cell-free circulating tumor DNA (ctDNA) has emerged as a promising biomarker in breast cancer. ctDNA is released into the…

Read More

The Importance of ctDNA in Breast Cancer Diagnosis and Treatment Planning Mridula George MD By Mridula George, MD Breast cancer (e.g., metastatic breast cancer) is the most common cancer in women worldwide, and early detection and personalized treatment are crucial for improving patient outcomes. Recently, the use of circulating tumor DNA (ctDNA) has emerged as a promising tool for the diagnosis and treatment of breast cancer. Initially, ctDNA (circulating tumor DNA) was mainly used in the metastatic setting, where it helped clinicians monitor disease progression and identify the most effective treatments. However, with the development of more sensitive assays, ctDNA…

Read More

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and Nab-paclitaxel for Pancreatic Cancer Treatment By Michael Pishvaian, MD, PhD Listen the to Audio Podcast: Stephanie Comello · David Lieberman, MD – Geneoscopy’s Colorectal Cancer Screening Test David Lieberman, MD – Geneoscopy’s Colorectal Cancer Screening Test Locally advanced pancreatic cancer has its own challenges because we’re really focused on trying to treat the tumor where it lies within the pancreas, while also treating the systemic micrometastatic disease that almost certainly is there. It’s also not usually a situation where we’re trying…

Read More

Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani By Virginia Kaklamani So after a patient’s cancer has progressed and and we’re talking about ER+ metastatic breast cancer in the first line setting, which we typically give a CDK4/6 inhibitor and endocrine therapy, we really don’t have a lot of good effective therapies. And the data that we’ve had since the use of CDK4/6 inhibitors has suggested a median PFS (progression-free survival) of anywhere between 3-5 months, with subsequent endocrine therapies. So this is why this field is extremely important in trying to find effective endocrine therapies…

Read More

iFrame is not supported! Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani By Virginia Kaklamani So after a patient’s cancer has progressed and and we’re talking about ER+ metastatic breast cancer in the first line setting, which we typically give a CDK4/6 inhibitor and endocrine therapy, we really don’t have a lot of good effective therapies. And the data that we’ve had since the use of CDK4/6 inhibitors has suggested a median PFS (progression-free survival) of anywhere between 3-5 months, with subsequent endocrine therapies. So this is why this field is extremely important in trying to…

Read More

FLEX Trial Breast Cancer: SABCS 2022 Mehran Habnibi MD Looking at Gene Mutations By Mehran Habibi, MD, MBA The new adjuvant hormone therapy and to treat the breast cancers that are estrogen positive in the US is not really something that we do a lot. So we do a lot of new adjuvant chemotherapies, but the new adjuvant hormone therapy has not really picked up. One of the reasons is that it takes quite some time for the hormone therapy to work and start to shrink the tumor to have a clinical response, around 3 months, sometimes 6 months or…

Read More

iFrame is not supported! FLEX Trial Breast Cancer: SABCS 2022 Mehran Habnibi MD Looking at Gene Mutations By Mehran Habibi, MD, MBA The new adjuvant hormone therapy and to treat the breast cancers that are estrogen positive in the US is not really something that we do a lot. So we do a lot of new adjuvant chemotherapies, but the new adjuvant hormone therapy has not really picked up. One of the reasons is that it takes quite some time for the hormone therapy to work and start to shrink the tumor to have a clinical response, around 3 months,…

Read More

Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani By Virginia Kaklamani So after a patient’s cancer has progressed and and we’re talking about ER+ metastatic breast cancer in the first line setting, which we typically give a CDK4/6 inhibitor and endocrine therapy, we really don’t have a lot of good effective therapies. And the data that we’ve had since the use of CDK4/6 inhibitors has suggested a median PFS (progression-free survival) of anywhere between 3-5 months, with subsequent endocrine therapies. So this is why this field is extremely important in trying to find effective endocrine therapies…

Read More

FLEX Trial Breast Cancer: SABCS 2022 Mehran Habnibi MD Looking at Gene Mutations By Mehran Habibi, MD, MBA The new adjuvant hormone therapy and to treat the breast cancers that are estrogen positive in the US is not really something that we do a lot. So we do a lot of new adjuvant chemotherapies, but the new adjuvant hormone therapy has not really picked up. One of the reasons is that it takes quite some time for the hormone therapy to work and start to shrink the tumor to have a clinical response, around 3 months, sometimes 6 months or…

Read More

Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the patient-reported outcomes from the TROPiCS-02 trial? So this year at San Antonio, we saw data from TROPiCS-02. This was a randomized phase 3 study that compared Sacituzumab Govitecan (SG), which is a novel antibody drug conjugate, to standard of care chemotherapy in patients with metastatic hormone receptor positive breast cancer. We’d seen results from this trial previously, initially at ASCO, we saw data regarding progression-free survival (PFS), demonstrating that Sacituzumab Govitecan (SG) led to an improvement in progression-free survival compared to chemotherapy in…

Read More

iFrame is not supported! Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the patient-reported outcomes from the TROPiCS-02 trial? So this year at San Antonio, we saw data from TROPiCS-02. This was a randomized phase 3 study that compared Sacituzumab Govitecan (SG), which is a novel antibody drug conjugate, to standard of care chemotherapy in patients with metastatic hormone receptor positive breast cancer. We’d seen results from this trial previously, initially at ASCO, we saw data regarding progression-free survival (PFS), demonstrating that Sacituzumab Govitecan (SG) led to an improvement in progression-free survival…

Read More

Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the patient-reported outcomes from the TROPiCS-02 trial? So this year at San Antonio, we saw data from TROPiCS-02. This was a randomized phase 3 study that compared Sacituzumab Govitecan (SG), which is a novel antibody drug conjugate, to standard of care chemotherapy in patients with metastatic hormone receptor positive breast cancer. We’d seen results from this trial previously, initially at ASCO, we saw data regarding progression-free survival (PFS), demonstrating that Sacituzumab Govitecan (SG) led to an improvement in progression-free survival compared to chemotherapy in…

Read More

Heterogeneity: SABCS 2022 Adrian Lee PhD Highlighted Research in Transcriptomics By Professor Adrian Lee How can heterogeneity in breast cancer metastasis highlighted research in transcriptomics help patients? So this year at SABCS (San Antonio Breast Cancer Symposium) we learned a lot about the heterogeneity of breast cancer. It’s helped us to understand the heterogeneity, and there was lots of talks and posters on new techniques and allow us to unravel the molecular features that have gone wrong in breast cancer and that’s helping us then direct therapies to them, and many of the clinical trials are using these new targets…

Read More

iFrame is not supported! Heterogeneity: SABCS 2022 Adrian Lee PhD Highlighted Research in Transcriptomics By Professor Adrian Lee How can heterogeneity in breast cancer metastasis highlighted research in transcriptomics help patients? So this year at SABCS (San Antonio Breast Cancer Symposium) we learned a lot about the heterogeneity of breast cancer. It’s helped us to understand the heterogeneity, and there was lots of talks and posters on new techniques and allow us to unravel the molecular features that have gone wrong in breast cancer and that’s helping us then direct therapies to them, and many of the clinical trials are…

Read More

Heterogeneity: SABCS 2022 Adrian Lee PhD Highlighted Research in Transcriptomics By Professor Adrian Lee How can heterogeneity in breast cancer metastasis highlighted research in transcriptomics help patients? So this year at SABCS (San Antonio Breast Cancer Symposium) we learned a lot about the heterogeneity of breast cancer. It’s helped us to understand the heterogeneity, and there was lots of talks and posters on new techniques and allow us to unravel the molecular features that have gone wrong in breast cancer and that’s helping us then direct therapies to them, and many of the clinical trials are using these new targets…

Read More

Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results By Mitul Gandhi, MD What were the results of the safety and efficacy of Brentuximab brand name ADCETRIS, in patients with Hodgkin Lymphoma? So this is a multi-center, multi-part study. Taking patients in this particular part B, evaluating patients with stage 2 bulky hodgkin’s lymphoma and stage 3 and 4 hodgkin lymphoma. The existing standard of care represents a combination of ABVD Adriamycin, Bleomycin, Vinblastine, Dacarbazine, often with omission of Bleomycin after PET stratification after cycle 2. Along with the newer standard of care based on the ECHELON-1 data…

Read More

iFrame is not supported! Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results By Mitul Gandhi, MD What were the results of the safety and efficacy of Brentuximab brand name ADCETRIS, in patients with Hodgkin Lymphoma? So this is a multi-center, multi-part study. Taking patients in this particular part B, evaluating patients with stage 2 bulky hodgkin’s lymphoma and stage 3 and 4 hodgkin lymphoma. The existing standard of care represents a combination of ABVD Adriamycin, Bleomycin, Vinblastine, Dacarbazine, often with omission of Bleomycin after PET stratification after cycle 2. Along with the newer standard of care based…

Read More

Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results By Mitul Gandhi, MD What were the results of the safety and efficacy of Brentuximab brand name ADCETRIS, in patients with Hodgkin Lymphoma? So this is a multi-center, multi-part study. Taking patients in this particular part B, evaluating patients with stage 2 bulky hodgkin’s lymphoma and stage 3 and 4 hodgkin lymphoma. The existing standard of care represents a combination of ABVD Adriamycin, Bleomycin, Vinblastine, Dacarbazine, often with omission of Bleomycin after PET stratification after cycle 2. Along with the newer standard of care based on the ECHELON-1 data…

Read More

Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim, MD How can Odronextamab help patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)? I presented here the interim analysis data for the next one, monotherapy, in patients with relapsed refractory DLBCL, in general, in patients who had the prior two or more lines of treatment. The outcome is quite disappointing in this Odronextamab clinical trial. The expected survivor was less than several months, and with the cytotoxic agent, we cannot have good until now. So here we, I’m presenting the other next monotherapy…

Read More

iFrame is not supported! Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim, MD How can Odronextamab help patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)? I presented here the interim analysis data for the next one, monotherapy, in patients with relapsed refractory DLBCL, in general, in patients who had the prior two or more lines of treatment. The outcome is quite disappointing in this Odronextamab clinical trial. The expected survivor was less than several months, and with the cytotoxic agent, we cannot have good until now. So here we, I’m presenting…

Read More

Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim, MD How can Odronextamab help patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)? I presented here the interim analysis data for the next one, monotherapy, in patients with relapsed refractory DLBCL, in general, in patients who had the prior two or more lines of treatment. The outcome is quite disappointing in this Odronextamab clinical trial. The expected survivor was less than several months, and with the cytotoxic agent, we cannot have good until now. So here we, I’m presenting the other next monotherapy…

Read More

Phase 3 ITHACA Study Results: Latest Insights on Isatuximab presented from ASH 2022 discussed by Dr. Irene Ghobrial from Dana-Farber Cancer Institute Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study We presented in the American Society of Hematology (ASH). Several abstracts related to MGUS and smoldering multiple myeloma. Some of them about risk stratification, who should be treated for smoldering myeloma because we know that many people are diagnosed with MGUS and smoldering myeloma… Read Article Watch Video Listen to Audio MRD: ASH 2022 Ben Derman the MRD2STOP Guide The study that we have conducted or we’re currently…

Read More

Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC By Jack West, MD Hi, I’m Dr. Jack West, and I’m a thoracic oncologist and associate professor at the City of Hope Comprehensive Cancer Center in the Los Angeles area. I wanted to take a minute to talk about the very recent FDA approval of pembrolizumab in the adjuvant setting for to treat patients with resected stage 1B to stage IIIA non-small cell lung cancer, and specifically how much or how little this FDA approval should translate to clinical use, or should we presume…

Read More

iFrame is not supported! Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC By Jack West, MD Hi, I’m Dr. Jack West, and I’m a thoracic oncologist and associate professor at the City of Hope Comprehensive Cancer Center in the Los Angeles area. I wanted to take a minute to talk about the very recent FDA approval of pembrolizumab in the adjuvant setting for to treat patients with resected stage 1B to stage IIIA non-small cell lung cancer, and specifically how much or how little this FDA approval should translate to clinical use,…

Read More

Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC By Jack West, MD Hi, I’m Dr. Jack West, and I’m a thoracic oncologist and associate professor at the City of Hope Comprehensive Cancer Center in the Los Angeles area. I wanted to take a minute to talk about the very recent FDA approval of pembrolizumab in the adjuvant setting for to treat patients with resected stage 1B to stage IIIA non-small cell lung cancer, and specifically how much or how little this FDA approval should translate to clinical use, or should we presume…

Read More

2023 ASH BCMA & Multiple Myeloma Updates with Slides by: Lisa Lee, MD – Assistant Professor — Division of Hematology-Oncology, Department of Medicine, UCI School of Medicine I wanna give you a quick update of the myeloma abstracts at ASH. And inevitably it’s gonna end up kind of focusing on the evolving saga over immunotherapies, because that’s the way that the field is heading. I have no conflicts of interest. So for those of you who treat myeloma, you know that we’re still plagued by this paradigm wherein we can’t tell patients that there’s a cure for their disease. Each subsequent…

Read More

ASH Meeting 2022 – Hematopoietic Stem Cell Transplantation with Tacrolimus Updates By Stefan O. Ciurea, MD from UCI Health So I talked about a couple of abstracts from ASH presented ASH this year. And one of the most important probably was the late breaking abstract 4 with post transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil GVHD Prophylaxis randomized to tacrolimus (Tac) plus methotrexate (MTX) for patients with hematologic malignancies, ongoing transplantation with a reduced intensity condition regimen. This was a BMT CTN study 1703, and this study showed that GRFS GVHD-free relapse-free survival was significantly better. With Post-Transplant Cyclophosphamide, Tacrolimus, and…

Read More

What ASH abstracts stood out to you most in multiple myeloma? By Lisa X. Lee, MD from UCI Health At ASH this year, it was all about immunotherapy for multiple myeloma. This year’s ASH came on the heels of two major approvals for BCMA directed CAR T, as well as our first approved BCMA bispecific. And I think, the question for people who treat myeloma is how can we improve upon these approved therapies? There were a lot of exciting abstracts and oral presentations on optimizing T-cell therapy, the cellular product itself. There are also interesting presentations on the sequencing…

Read More

Myelodysplastic Syndromes Treatment Update for 2023 By Deepa Jeyakumar, MD from UCI Health I think what’s very exciting is that in the past year we’ve seen multiple different agents that are available for patients, giving them more options for these difficult to treat diseases in low risk MDs. We have seen the initial results. With a telomerase inhibitor, which will hopefully prove beneficial in patients with lower risk MDs and complete transfusion independence, patients can spend less time in the infusion centers getting blood transfusions and more time outliving their lives. In higher risk MDs, there are multiple different options…

Read More

Zanubrutinib compared to ibrutinib in chronic lymphocytic leukemia By Elizabeth Brém, MD from UCI Health We focused basically on two major as abstracts from ASH this year. One of which was a late breaking abstract called the Aspen Study, which was Zanubrutinib versus Ibrutinib in treatment of CLL, which showed a progression-free survival benefit for Zanubrutinib, and actually led to a recent FDA approval for Zanubrutinib for treatment of CLL. And we also talked about the triangle study, which had been presented at the plenary, looking at whether or not we should incorporate Ibrutinib into our standard of care…

Read More

Women with recurrent miscarriage were treated with low molecular weight heparin versus usual pregnancy care By Zahra Pakbaz, MD from UCI Health Today was mainly MOASC Hematology Spotlight, and my session was about nonmalignant hematology. So I tried to summarize some of the abstracts which were presented at ASH. But because of, it’s a garden variety of diseases are all bunched up in non-cancer blood disorders. So I decided to pick the two benign hematology late breaking abstracts. One was about PNH (Paroxysmal nocturnal hemoglobinuria) and the new development of an overall medication complement inhibitor and B factor, B inhibitor,…

Read More

ASH Meeting 2022 – Hematopoietic Stem Cell Transplantation with Tacrolimus UpdatesBy: Stefan O. Ciurea, MD – Director, Hematopoietic Stem Cell Transplantation and Cellular Therapy Program University of California IrvineI was asked to talk about ab ASH updates and I selected 13 abstracts. I’m gonna go through them very fast if we’re already late. I have about 50 slides, first abstract I wanna talk about is this late breaking abstract, which is in fact first results from a randomized phase three trial done by BMT CTN. comparing two methods of GVHD prophylaxis with post transplantation, cyclophosphamide, Tacrolimus, MMF versus tacrolimus, methotrexate,…

Read More

iFrame is not supported! Inotuzumab and MRD Understanding the Importance of Targeted Therapy in Cancer Treatment Summarized from Van Huynh, MD’s video on MRD: 2023 ASH ALL Inotuzumab Update [Slides] – MOASC Hematological malignancies like acute lymphoblastic leukaemia (AML) are diseases that affects millions of people worldwide, and it is essential to have effective treatments that can target the specific type of cancer and its underlying genetic mutations. Targeted therapy is a type of cancer treatment that aims to inhibit the specific genetic mutations or proteins that drive the growth of cancer cells. In this article, we will explore the…

Read More

Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer By Paula Novelli, MD At this year’s ASCO GI Symposium (in January 2023), our team presented intra-arterial gemcitabine versus intravenous gemcitabine PK substudy data within the RenovoRx TIGeR-PaC Phase III clinical trial. In a cohort of 13 patients, 7 patients were in the intra-arterial arm and 6 patients, the intravenous arm. Despite a 30% increased concentration in infusion in the intra-arterial arm, there was an average of 50% reduction in systemic drug exposure which is significant based on the entire concept…

Read More

iFrame is not supported! Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer By Paula Novelli, MD At this year’s ASCO GI Symposium (in January 2023), our team presented intra-arterial gemcitabine versus intravenous gemcitabine PK substudy data within the RenovoRx TIGeR-PaC Phase III clinical trial. In a cohort of 13 patients, 7 patients were in the intra-arterial arm and 6 patients, the intravenous arm. Despite a 30% increased concentration in infusion in the intra-arterial arm, there was an average of 50% reduction in systemic drug exposure which is significant based…

Read More

Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer By Paula Novelli, MD At this year’s ASCO GI Symposium (in January 2023), our team presented intra-arterial gemcitabine versus intravenous gemcitabine PK substudy data within the RenovoRx TIGeR-PaC Phase III clinical trial. In a cohort of 13 patients, 7 patients were in the intra-arterial arm and 6 patients, the intravenous arm. Despite a 30% increased concentration in infusion in the intra-arterial arm, there was an average of 50% reduction in systemic drug exposure which is significant based on the entire concept…

Read More

Myelodysplastic Syndromes Treatment Update for 2023 ASH AML Inotuzumab Update [Slides] – Kiran Naqvi, MD MOASC By Kiran Naqvi, MD So today my talk was mainly highlighting the ASH abstracts or ash highlights of 2022. And I had the pleasure of presenting several abstracts, actually all of them, which I felt were really important. But some of the few that I wanted to mention that I think are important now is that we have really good experience with chemotherapy in our younger patients. And with the combination of Cytarabine, with Idarubicin or Anthracycline. But now we need to talk more…

Read More

MRD: Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia/Immunotherapy By Van Huynh, MD Today I spoke at MOASC (Medical Oncology Association of Southern California), and the focus was on acute lymphoblastic leukemia, or ALL, along with any new updates on immunotherapy in this population. Did anything stand out to you about these clinical trials? So I presented on three separate studies, and I think the general theme was that it acknowledged that the overall survival rate for adults with ALL (acute lymphoblastic leukemia) has historically been poor. But there have been many. There have been…

Read More

Myelodysplastic Syndromes Treatment Update for 2023 So briefly with regard to myelodysplastic syndromes MDS, I just wanted to discuss some of the proposed changes to classification, as well as some of the changes and updates and low-risk myelodysplastic syndromes, as well as high-risk myelodysplastic syndromes. So in June of 2022, the molecular international prognostic score was proposed. This has been long awaited based. Previously, we were using the I P S R. The problem with that system is that it didn’t include some of the important molecular findings that re leukemia were affecting outcome. So the purpose of the update…

Read More

Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia By Van Huynh, MD Updates in acute lymphoblastic leukemia that was presented at ASH in New Orleans. So I think there were so many great talks. There were so many great talks and I decided I would focus on just three and really go into the details of each of those talks. I think there’s a theme there. So the first will be The trial by the gm, o l, which is the outcome of patients with newly diagnosed pH negative ALL treated according to a pediatric based regimen.…

Read More

Zanubrutinib compared to ibrutinib in chronic lymphocytic leukemia So I’m gonna start with chronic lymphocytic leukemia. And as part of late-breaking abstracts, we got this study which was zanubrutinib compared to ibrutinib before chronic lymphocytic leukemia.Relatively straightforward study design. These were previously treated patients, so one prior systemic therapy, measurable disease, no prior BTK inhibitors, and they were randomized one to one to zanubrutinib or ibrutinib. The primary endpoint was progression-free survival and treatment continued until progression or toxicity.And this was obviously a randomized study, so it was relatively balanced. The median age was about right for chronic lymphocytic leukemia…

Read More